NCT04622046View on ClinicalTrials.gov

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

November 8, 2023

Study Completion Date

September 23, 2025

Conditions
Symptomatic Transthyretin Amyloid Cardiomyopathy
Interventions
DRUG

ALXN2060

ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.

Trial Locations (11)

113-8431

Research Site, Bunkyō City

812-8582

Research Site, Fukuoka

860-8556

Research Site, Kumamoto

830-0011

Research Site, Kurume-shi

390-8621

Research Site, Matsumoto-shi

466-8560

Research Site, Nagoya

783-8505

Research Site, Nankoku-shi

252-0375

Research Site, Sagamihara-shi

060-8543

Research Site, Sapporo

160-8582

Research Site, Shinjuku-ku

564-8565

Research Site, Suita-shi

Sponsors
All Listed Sponsors
collaborator

Eidos Therapeutics, a BridgeBio, Inc. Company

UNKNOWN

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY